## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract
- **Shared manuscript claim summary** The authors propose a deep learning model combining convolutional neural networks and long short-term memory to predict transcription factor binding sites on cell-free DNA from sequence information. They report an area under the curve of 84%, consistent motif discovery in cfDNA fragments, lower coverage upstream and downstream of these fragments, TF binding site differences across cell lines, and TF-specific target genes enriched in cancer-related pathways.
- **Visible evidence base** Abstract text only; no figures, tables, methods details, or supplementary materials provided
- **Missing materials affecting confidence** Full manuscript, model architecture details, training and validation datasets, performance metrics beyond AUC, motif analysis methodology, cell line comparison details, pathway enrichment statistics, and any code or data availability statements

## Reviewer
- **Overall assessment** The abstract presents a potentially useful application of deep learning to noninvasive TFBS prediction from cfDNA. The reported AUC of 84% suggests reasonable predictive performance, and the downstream biological observations are interesting. However, the abstract lacks sufficient methodological detail and statistical rigor to fully evaluate the validity and generalizability of the claims. Several assertions are made without supporting quantitative evidence, and the relationship between model predictions and biological interpretations requires clarification.
- **Who would be interested in the results, and why** Researchers in computational biology, epigenomics, and liquid biopsy would be interested. Those working on transcription factor binding prediction, cfDNA-based diagnostics, and noninvasive disease monitoring would find the approach relevant. Clinicians interested in dynamic disease monitoring through plasma-based assays may also find the potential applications appealing.
- **Major strengths** The study addresses a clinically relevant problem, namely noninvasive identification of TFBS from cfDNA. The combination of CNN and LSTM architectures is a reasonable approach for sequence-based prediction. The authors connect model predictions to biological observations, including motif consistency and pathway enrichment, which adds translational relevance.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
  - R1-M4
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** The abstract does not provide sufficient information on dataset composition, cross-validation strategy, baseline comparisons, or statistical significance of biological findings. Without these, the core predictive claim and the downstream biological interpretations cannot be fully assessed.
- **Assessment against Nature-style criteria** Originality is moderate, as deep learning for TFBS prediction is an active area, though the cfDNA application adds a novel angle. Scientific importance is potentially high given the noninvasive clinical implications, but the evidence base is too thin to establish significance. Interdisciplinary readership is plausible, spanning computational and clinical communities. Technical soundness cannot be adequately evaluated from the abstract alone. Readability for nonspecialists is acceptable, though some terms such as "long short-term memory" and "area under the curve" may require brief explanation for a broader audience.
- **Recommendation posture** Supportive if technical concerns are resolved, but currently not established from the provided evidence.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Technical soundness
- **Claim pointer** The model achieved an area under the curve of 84%.
- **Evidence pointer** Abstract, location not provided
- **Concern** The abstract reports a single AUC value without specifying the dataset, the number of TFBS instances, the genomic context, the train-test split, or whether performance was evaluated on held-out chromosomes or cell types. No comparison to existing methods is provided.
- **Why it matters** AUC alone is insufficient to establish predictive utility. Without knowing the data composition and evaluation protocol, the reported performance could be inflated by data leakage, class imbalance, or overfitting. The absence of baseline comparisons prevents assessment of whether the method advances the state of the art.
- **Resolution test** Provide detailed dataset description, cross-validation or independent test set results, precision-recall metrics, and comparison with at least one established TFBS prediction method.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Reproducibility
- **Claim pointer** The model learns sequence information from known TFBSs through convolutional neural networks with long short-term memory.
- **Evidence pointer** Abstract, location not provided
- **Concern** No architectural details, hyperparameter settings, training procedure, or software implementation are described. The abstract does not state whether the model and code are publicly available.
- **Why it matters** Reproducibility is a core requirement for computational studies. Without these details, other researchers cannot validate or build upon the work, and the technical claims cannot be independently verified.
- **Resolution test** Include a methods section with full architecture description, training details, and a data or code availability statement.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Statistical rigor
- **Claim pointer** Consistent motifs were found in cfDNA fragments, and lower coverage occurred upstream and downstream of these fragments, consistent with a previous study. Binding sites of the same TF differ in different cell lines. TF-specific target genes were enriched in cancer-related pathways.
- **Evidence pointer** Abstract, location not provided
- **Concern** These biological claims are presented without any statistical measures, such as enrichment scores, p-values, confidence intervals, or effect sizes. The consistency with a previous study is mentioned but not quantified. The cell line comparison and pathway enrichment are stated without supporting data.
- **Why it matters** Biological interpretations derived from computational predictions require statistical validation to rule out chance findings. Without quantitative support, these claims remain anecdotal and cannot be evaluated for robustness or biological significance.
- **Resolution test** Provide statistical tests and effect sizes for motif enrichment, coverage analysis, cell line comparisons, and pathway enrichment, including multiple testing corrections where applicable.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** No
- **Axis** Generalizability
- **Claim pointer** The method can noninvasively predict TFBSs of cfDNA and has potential for clinical monitoring.
- **Evidence pointer** Abstract, location not provided
- **Concern** The abstract does not specify the number of TFs studied, the diversity of cell types or tissues represented, or whether the model generalizes across different sequencing platforms or cfDNA preparation methods. The clinical potential is stated without any validation in patient samples.
- **Why it matters** Generalizability is essential for clinical applicability. If the model is trained and tested on limited TF or cell type contexts, its utility for broader clinical use remains uncertain.
- **Resolution test** Describe the scope of TFs and cell types covered, test on independent datasets from different sources, and discuss limitations regarding clinical translation.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract wording
- **Evidence pointer** Abstract, location not provided
- **Issue** The phrase "lower coverage occurred upstream and downstream of these cfDNA fragments" is ambiguous. It is unclear whether this refers to genomic coverage around the predicted binding sites or coverage within the cfDNA fragments themselves.
- **Required correction** Clarify the genomic context and the directionality of the coverage observation.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Completeness
- **Affected element** Performance reporting
- **Evidence pointer** Abstract, location not provided
- **Issue** Only AUC is reported. Other metrics such as precision, recall, F1 score, or area under the precision-recall curve are not mentioned, which would be informative given potential class imbalance in TFBS prediction.
- **Required correction** Report additional performance metrics, particularly precision-recall based measures.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Context
- **Affected element** Related work
- **Evidence pointer** Abstract, location not provided
- **Issue** The abstract does not situate the proposed method relative to existing deep learning approaches for TFBS prediction, such as those using convolutional networks on chromatin or sequence data.
- **Required correction** Briefly mention prior computational methods and state the specific novelty of the cfDNA application.

## Risk / unsupported claims
- The claim that the model can "noninvasively predict TFBSs of cfDNA" is supported only by a single AUC value without external validation.
- The claim that "consistent motifs" were found is unsupported without motif enrichment statistics or comparison details.
- The claim that "binding sites of the same TF differ in different cell lines" is unsupported without quantitative comparison data.
- The claim that TF-specific target genes "were enriched in cancer-related pathways" is unsupported without enrichment scores or p-values.
- The claim of "potential to reflect the intrinsic regulatory mechanism" and "provide technical guidance for clinical practice" is speculative and not substantiated by the evidence presented.